Clinical results analyze dexamethasone implant effect on macular thickness

Video
Conference|ARVO

Dr. Daniel F. Kiernan discusses key findings of a clinical study analyzing the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on OCT testing following vitreoretinal surgery.

Dr. Daniel F. Kiernan, a vitreoretinal surgeon at The Eye Associates, Sarasota, Florida, discusses the highlights of his 2021 ARVO virtual presentation on the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on optical coherence tomography (OCT) testing following vitreoretinal surgery.

See more ARVO coverage

Recent Videos
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
2 experts in this video
3 experts are featured in this series.
2 experts in this video
Related Content
A patient undergoes eye surgery, surrounded by doctors in protective surgical gear. Image credit: ©st.kolesnikov – stock.adobe.com

Postoperative considerations for retinal detachments following keratoprosthesis implantation

Lynda Charters
February 21st 2025
Article

Risk factors vary in both short-term and long-term periods following Boston Type 1 keratoprosthesis surgery

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A person holds a tablet which displays results from the Dr.Noon CVD tool, which uses retinal scans to screen for cardiovascular disease. Image courtesy of Heart Eye.

Heart Eye announces AI-driven retinal imaging system to detect biomarkers of cardiovascular health risks

Hattie Hayes
February 19th 2025
Article

The UK-based company will debut the tool, called Dr.Noon CVD, at two conferences in March

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A crystal ball sits on a small platform, surrounded by misty fog. ©alexkich – stock.adobe.com

Retinal biomarkers in OCT imaging may have predictive applications for nAMD

Lynda Charters
February 17th 2025
Article

The authors evaluated shallow irregular pigment epithelial detachment, subretinal hyperreflective material, subretinal fluid, intraretinal fluid and other baseline OCT biomarkers

A nurse in scrubs and glasses helps his elderly patient stretch and exercise. Image credit: ©Jacob Varghese – baseimage

Healthy lifestyles translate to lower risk of retinal disease

Lynda Charters
February 12th 2025
Article

Researchers screened for outcomes such as the presence of retinal diseases including age-related macular degeneration and retinal vein occlusion

© 2025 MJH Life Sciences

All rights reserved.